Payers Move Against Avastin: California Blue Shield Halting Coverage In Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Announcement follows similar moves by three smaller commercial payers earlier this year.
You may also be interested in...
Implications Of Avastin Breast Cancer Withdrawal Already Felt
Now that the FDA has pulled the plug on Avastin’s metastatic breast cancer indication, the implications for Roche may not be as far-reaching as many suspect.
NCCN Guidelines Reaffirm Support For Avastin In Metastatic Breast Cancer
The influential NCCN Clinical Practice Guidelines for Oncology should retain its recommendation supporting use of Genentech/Roche’s Avastin (bevacizumab) in metastatic breast cancer, the National Comprehensive Cancer Network expert breast cancer panel voted 24-0, with 1 abstention, at its July 10-12 meeting. NCCN recommendations are often used by payers in establishing formulary and coverage policies.
Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?
FDA Commissioner Margaret Hamburg faces a decision on the future of Avastin’s (bevacizumab) first-line metastatic breast cancer claim that may not be so cut and dried as the Oncologic Drugs Advisory Committee’s unanimous vote favoring the indication’s withdrawal suggests.